LTR PHARMA LIMITED — Capital/Financing Update 2024

Dec 5, 2024

Market Announcement

==> picture [33 x 50] intentionally omitted <==

6 December 2024

==> picture [451 x 5] intentionally omitted <==

LTR Pharma Limited (ASX: LTP) – Trading Halt

Description

The securities of LTR Pharma Limited (‘LTP’) will be placed in trading halt at the request of LTP, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 10 December 2024 or when the announcement is released to the market.

Issued by

ASX Compliance

Market Announcement 1/1 ASX Customer Service Centre 131 279 | asx.com.au

6 December 2024 ASX Limited

#10837674v1

==> picture [596 x 64] intentionally omitted <==

6 December 2024

Melissa Kostopoulos ASX Compliance Pty Limited Level 4, North Tower, Rialto 525 Collins Street Melbourne VIC 3000

By email: tradinghaltsmelbourne@asx.com.au

Dear Melissa

TRADING HALT REQUEST – ASX CODE: LTP

LTR Pharma Limited ( ASX:LTP ) (“LTR Pharma”, “the Company”), requests a trading halt in respect of its securities pursuant to Listing Rule 17.1 with immediate effect.

In accordance with ASX Listing Rule 17.1, LTR Pharma advises that:

1. The trading halt is necessary pending a material annoucment relating to a capital raise.

2. LTR Pharma requests that the trading halt remain in place until the Company releases an announcement in relation to the capital raise or until the commencement of trading on Tuesday 10 December 2024, whichever is earlier;

3. LTR Phama confirms that it is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market regarding the trading halt.

Kind regards

Belinda Cleminson Company Secretary

About LTR Pharma

LTR Pharma is focused on improving men’s health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma’s lead product SPONTAN[®] is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.

1800 519 711 | ltrpharma.com | info@ltrpharma.com

LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)